## Background

- SBMA, also known as Kennedy disease, is an X-linked inherited motor neuron disease.
- The diagnostic odyssey can last several years for people with SBMA.
- Clinical management involves symptom management and multi-disciplinary care; best-practicing sharing can help optimize care.
- This document captures highlights from an MDA webinar with a SBMA expert.
- View the companion webinar here.


#### **Overview**

Description <sup>1,2</sup>	Epidemiology <sup>2,3</sup>	Onset and Prognosis <sup>1,4</sup>
<ul> <li>Affects males (androgen- dependent)</li> <li>Caused by a CAG repeat expansion in exon 1 of the androgen receptor gene <ul> <li>Occurs when it</li> </ul> </li> </ul>	<ul> <li>Prevalence: 1 in 40,000</li> <li>Reported in as many as 1 in 7,000 males</li> </ul>	<ul> <li>Age of onset: mid-40s</li> <li>Disease progresses slowly (~2% decline per year)         <ul> <li>Patients may become wheelchair-dependent 20-30 years after</li> </ul> </li> </ul>
<ul> <li>exceeds 37 repeats</li> <li>Characterized by slowly progressive lower motor neuron loss, muscle weakness, and other non- neuromuscular symptoms</li> </ul>		onset <ul> <li>Majority of patients have normal life expectancy</li> </ul>

CAG, cytosine-adenine-guanine.

1. Rhodes LE, et al. *Brain.* 2009:132;3242-3251. 2. Zanovello M, et al. *Brain.* 2023:146(7);2723-2729. 3. Grunseich C, et al. *Oral Dis.* 2014;20(1):6-9. 4. Arnold FJ, Merry DE. *Neurotherapeutics.* 2019;16(4):928-947.

## **Genetic Etiology**



AR, androgen receptor; CAG, cytosine-adenine-guanine; SBMA, spinal-bulbar muscular atrophy. 1. La Spada A. Spinal and bulbar muscular atrophy. In: *GeneReviews*<sup>®</sup> [Internet]. Seattle, WA: University of Washington, Seattle; 1993-2024.

Developed with the expertise of Christopher Grunseich, MD, Investigator, NINDS, National Institute of Health, Bethesda, MD



Clinical Manifestations				
Neuromuscular dysfund	tions <sup>1,2</sup>	Other mai	nifestations <sup>1</sup>	
Loss of lo motor ne from brai and spina	urons nstem	<ul> <li>Androgen insensitivity (gynecomastia, infertility, testicular atrophy)</li> </ul>		levated K
Proximal muscle at weakness	rophy and	<ul> <li>Altered metabolism (nonalcoholic fatty liver disease, insulin resistance, cholesterol, and triglycerides)</li> </ul>		Sensory neuropathy
		Average · E	Brugada syndrome	


CK, creatine kinase.

1. Arnold FJ, Merry DE. Neurotherapeutics. 2019;16(4):928-947. 2. Grunseich C, et al. Oral Dis. 2014;20(1):6-9.

### **Slow Disease Progression**

#### Age distribution of ADL milestones (median)<sup>1</sup>

Based on 223 patients with SBMA and a mean of 46.6 CAG repeats (range 40-57)




ADL, activities of daily living; CAG, cytosine-adenine-guanine; SBMA, spinal-bulbar muscular atrophy. 1. Atsuta N, et al. *Brain.* 2006;129:446-1455. 2. Rhodes LE, et al. *Brain.* 2009;132:3242-3251.



Developed with the expertise of Christopher Grunseich, MD, Investigator, NINDS, National Institute of Health, Bethesda, MD

## **Diagnosis of SBMA**



CAG, cytosine-adenine-guanine; CK, creatine kinase; EMG, electromyogram; NCS, nerve conduction study; SBMA, spinal-bulbar muscular atrophy; ULN, upper limit of normal. 1. Grunseich C, zet al. *Oral Dis.* 2014;20(1):6-9.

# **Multidisciplinary Team**

#### SPEECH THERAPIST<sup>1,2</sup>

Preserve oral communication

#### PHYSICAL THERAPIST<sup>1,2</sup>

- Support adapted exercise
- Prevent painful musculoskeletal complications of poor mobility

#### PULMONOLOGIST<sup>1,2</sup>

- Monitor respiratory function and prevent infections
- Evaluate need for respiratory support (cough assist/ noninvasive ventilation)

#### ENDOCRINOLOGIST<sup>1,2</sup>

 Monitor metabolic parameters, including cholesterol and insulin resistance

#### NEUROLOGIST<sup>1,2</sup>

- Establish diagnosis
- Ensure coordination of care

#### DIETICIAN<sup>1,2</sup>

- Advice on dietary adaptation to bulbar function
- Food supplements
- Formal swallowing evaluation

#### OCCUPATIONAL THERAPIST<sup>1,2</sup>

- Support necessary adaptation to physical disability (provide adapted environment and assistive device)

### SOCIAL WORKER<sup>1</sup>

- Educate patients on genetic risks and financial resources available
- Monitor cardiac function and arrhythmias (Brugada syndrome)

1. Pradat PF, et al. Orphanet J Rare Dis. 2020;15(1):90. 2. La Spada A. Spinal and bulbar muscular atrophy. In: GeneReviews<sup>®</sup> [Internet]. Seattle, WA: University of Washington, Seattle; 1993-2024.

caregivers


PSYCHOLOGIST<sup>1</sup>

Provide psychological

support to patients and



### SBMA Research



# Therapies for SBMA in Pipeline

	PRECLINICAL PHASE 1/2 PHASE 3
<b>AJ201</b> activation of Nrf2 (US)	Phase 1/2a randomized, double-blind study to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of AJ201 in patients with SBMA ( <u>NCT05517603</u> ) <sup>1,2</sup>
<b>Clenbuterol</b> Beta-2 agonist (Italy)	Phase 2 placebo-controlled study of clenbuterol in patients with SBMA (BetaSBMA - <u>NCT06169046</u> ) <sup>3</sup>
NIDO-361 Androgen receptor allosteric modulator (Denmark, Italy, Republic of Korea, UK)	Phase 2 randomized, double-blind, placebo- controlled study of NIDO-361 in patients with SBMA (PIONEER KD - NCT06411912) <sup>4,5</sup>

Nrf2, nuclear factor erythroid 2-related factor 2; SBMA, spinal-bulbar muscular atrophy. 1. Product pipeline. AnnJi Pharmaceuticals website. https://www.ajpharm.com/product-pipeline/. 2. A study to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of AJ201 in patients. ClinicalTrials.gov website. https://clinicaltrials.gov/study/NCT05517603. 3. A placebo-controlled study of clenbuterol in spinal and bulbar muscular atrophy (BetaSBMA). ClinicalTrial.gov website. https://clinicaltrials.gov/study/NCT06169046. 4. Pushing the boundaries of neuroscience. NIDO Biosciences website. https://nidobio.com/. 5. A Study of NIDO-361 in Patients With SBMA (PIONEER KD). ClinicalTrial.gov website. https://clinicaltrials.gov/study/NCT06411912.



Developed with the expertise of Christopher Grunseich, MD, Investigator, NINDS, National Institute of Health, Bethesda, MD

antisense oligonucleotide; BDNF, brain-derived

cyclase-activating polypeptide; PI3K,

2023;71:102394.

Marchioretti C, et al. Curr Opin Pharmacol.

A Resource for Clinicians

## **SBMA Patient Registry**



https://research.sanfordhealth. org/rare-disease-registry

- Help to facilitate enrollment into future clinical studies
- Planning and design of future clinical studies
- Information shared with qualified research teams

Image from Sanford Research. https://research.sanfordhealth.org/rare-disease-registry

# **SBMA Clinical Resources**





Access companion MDA webinar here

